


# EyeMax Mono

The IOL Designed to Maximize  
Macular Vision in AMD patients






Dry AMD vision\*

EyeMax Mono is an extended macular vision IOL uniquely designed to **improve vision in patients with dry AMD** and other retinal diseases.

\*For illustrative purposes only. Degree of visual impairment and post procedure results will vary.




**After EyeMax Mono  
Implantation\***

The unique design of EyeMax Mono utilises transverse asphericity to extend the breadth of focus, enabling delivery of a sharper image to the naturally occurring preferred retinal locus (PRL) that may develop in response to central macular dysfunction.



## EyeMax Mono is an extended macular vision IOL uniquely designed to increase the range of focus and consequently improve the quality of vision in patients with dry AMD

- To compensate for the loss in macular function, in some patients fixation may shift to a healthier part of the macula and a preferred retinal locus (PRL) may naturally form<sup>6</sup>
- Working with this natural adaptation process, EyeMax Mono utilises transverse asphericity to extend the breadth of focus and deliver a sharper image to this naturally formed PRL.<sup>1-3</sup>



- Most of the IOLs available on the market are designed with a narrow range of focus, usually around 5° from the fovea - and this standard design does not take into account that the atrophy may have already reached areas of the retina within the 5°.
- EyeMax Mono is uniquely designed to provide quality vision within an area up to 10° from the fovea across the macula, providing a retinal area of focus that is 4-times larger than that of other IOLs.



# EyeMax Mono: A unique optical innovation designed to improve visual acuity and function

## SIMPLICITY

- EyeMax Mono surgery is a standard cataract procedure
- No additional training is required for the surgeon, nor any rehabilitation for the patient <sup>1,2,7</sup>
- No additional surgical intervention required as AMD progresses: the patient's brain finds a new PRL within the area 10° from the fovea - provided AMD has not already fully deteriorated the area 10° from the fovea.

- Foldable, injectable, single-piece IOL
- Square-edge design
- UV-absorbing, hydrophobic, soft, yellow acrylic
- Design accounts for chromatic and spherical aberration



## RESULTS

- Mean visual acuity gains of up to 18 ETDRS letters <sup>2,5\*</sup>
- Mean CDVA improvement of 0.25 logMAR in non-significant cataract eyes<sup>9</sup>
- Improved image quality due to the optimised IOL optical design for AMD eyes
- Image magnifications of 1.1-1.2x<sup>8</sup>

\*Mean gain in ETDRS letters at a mean post-operative follow-up of 7 months<sup>4</sup>

# RESULTS

## Clinically Proven Efficacy and Safety

EyeMax Mono is **safe and effective** in patients with AMD and cataract, with published data now covering nearly 700 eyes.

Studies consistently report meaningful improvements in both distance and near vision, particularly in patients with intermediate to advanced dry AMD.

### Core EMM patients

#### Intermediate to advanced AMD & Cataract

**196 eyes<sup>(10)</sup>**

CDVA:  **$\geq +2$  lines** in **>50% of eyes**  
CNVA:  $\geq +1$  lines even in 35% of late AMD eyes

**244 eyes<sup>(2)</sup>**

Mean CDVA: improved **3.5 lines**  
Mean CNVA: improved **4.8 lines**

**22 eyes<sup>(11)</sup>**

Mean CDVA: improved **3.3 lines**

**22 eyes<sup>(12)</sup>**

CDVA:  **$\geq +2$  lines in all eyes**  
Progressive CDVA/CNVA improvement

**30 eyes<sup>(13)</sup>**

Regain functional vision without PRL training;  
maintains VA as AMD advances

**21 eyes<sup>(14)</sup>**

Mean CDVA: +2 lines,  **$\geq +3$  lines** in **~33% of eyes**  
Microperimetry improvement in >50% of eyes, driven by IOL design  
(not by cataract removal)





## Efficacy Beyond Cataract Removal

### AMD & Non-Visually Significant Cataract

**113 eyes<sup>(9)</sup>** (up to 9 yrs follow-up, avg. >4 years)  
CDVA: **≥+3/ +2/ +1 line** in **35%/ 69%/ 95% of eyes**  
CNVA: **≥+1 lines** in >50% of eyes

**30 eyes<sup>(15)</sup>**  
**100% improved CDVA**  
and **97% improved CNVA** in advanced AMD cases

**8 eyes<sup>(1)</sup>**  
Mean CDVA: improved **3.4 lines**  
Microperimetry sensitivities from 8.2 to 12

**6 eyes<sup>(16)</sup>**  
BCVA improved **2-4 lines**

Published data in eyes with AMD and non-visually significant cataract highlight the role of the IOL's optical design in enhancing image quality by optimizing the use of healthier retinal areas.

References: (1) Robbie, et al. *J Refract Surg* 2018; (2) Qureshi, et al. *Eur J Ophthalmol* 2018; (3) Grzybowski, et al. *Ann Transl Med*. 2020; (4) Chakrabarti, et al. Available at: [bit.ly/sharpview\\_chakrabarti](https://bit.ly/sharpview_chakrabarti). Accessed Sep 2021; (5) Huynh, et al. *Ophthalmology* 2014; (6) Ramírez Estudillo, et al. *Int J Retin Vit.* 2017; (7) Badala, et al., *AAO*, 2018. (8) Grzybowski, Wang, Mao, et al., *Ann Transl Med* 2020; (9) Badalà, Bona, Devincenzi, Nouri-Mahdavi, *Clin Ophthalmol*, 2024; (10) Hengerer et al, *BMC Ophthalmology* 2025; (11) Gobeka, Erakgün, *Irish J Med Science*, 2023; (12) Hengerer, Auffarth, *Ophthalmol Retina*, 2018; (13) Busatto, *Modern Retina*, 2023; (14) Stanzel, Bedersdorfer, Szurman, Boden, *Euretina*, 2025; (15) Marin, *ESCRS*, 2023; (16) Villegas, Artal, *Invest Ophthalmol Vis Sci*, 2017.



# PATIENT SELECTION

- **AMD with cataract**

Patients with **dry AMD** and **stable wet AMD** undergoing cataract surgery, when healthy macular areas remain within **10° of the fovea**.

- **AMD without visually significant cataract**

Evidence supports implantation in AMD patients where cataract is not visually limiting.

- **Other retinal diseases**

Suitable for patients with a range of macular diseases and stable fixation, such as macular hole, Stargardt disease, macular scar, CSR, macular pucker, and AVL.

The safety profile of EyeMax Mono is comparable to standard monofocal IOLs, with no safety concerns or explantation issues reported in the literature.

.....



✉ [INFO@SHARVIEWOPHTHALMOLOGY.COM](mailto:INFO@SHARVIEWOPHTHALMOLOGY.COM)

[SHARVIEWOPHTHALMOLOGY.COM](http://SHARVIEWOPHTHALMOLOGY.COM)

Distributed by

**Medilas AG** / Zürcherstrasse 39E / CH-8952 Schlieren  
[www.medilas.ch](http://www.medilas.ch) / [info@medilas.ch](mailto:info@medilas.ch) / +41 44 747 40 00



📍 **EyeMax Mono is available, or will be available subject to registration, in:**

**Europe** Albania **Austria** Belgium **Bosnia and Herzegovina** Bulgaria Croatia Cyprus **Czech Republic** Denmark **Estonia** Finland **France** Georgia **Germany** Greece **Hungary** Iceland **Ireland** Italy **Kosovo** Latvia **Liechtenstein** Lithuania **Luxembourg** Malta **Moldova** Netherlands **North Macedonia** Norway **Poland** Portugal **Romania** Serbia **Slovakia** Slovenia **Spain** Sweden **Switzerland** Turkey **Ukraine** **Middle East** Oman **Qatar** **Africa** South Africa **Asia-Pacific** Australia **Hong Kong** New Zealand **Latin America** Argentina **Caribbean** Chile **Colombia** Ecuador **Mexico** Peru



EyeMax Mono™ is a registered trademark of Sharpview Ophthalmology Limited  
Job Bag number: SHV/EMM/001/a | Date of preparation: March 2025

EyeMax Mono is designed to optimise visual outcomes in patients with dry AMD. Please refer to the Instructions For Use. Adverse events should be reported as soon as possible to [eventreporting@sharpviewophthalmology.com](mailto:eventreporting@sharpviewophthalmology.com)